0
0
A recent study published in JAMA Network Open has revealed a significant correlation between gender-affirming hormone therapy and a reduced risk of depression among transgender, nonbinary, and gender-diverse individuals. The research, conducted by Sari Reisner, associate professor of epidemiology at the University of Michigan School of Public Health, and colleagues, suggests that hormone therapy not only provides physical benefits but also contributes to improved mental health outcomes.
The study analyzed data from 3,592 patients at community health centers in Boston and New York over a four-year period. Researchers compared the depression levels of patients who received hormone therapy with those who did not, using the Patient Health Questionnaire. The findings indicated that individuals who underwent hormone therapy had a 15% lower risk of experiencing moderate to severe depression during the follow-up period.
“Trans people experience mental health disparities with higher rates of depression and suicidality than cisgender (non-transgender) people,” Reisner told CNN. “Trans people are literally dying. There is an urgent need—now more than ever—to care for us, support us, and ensure we have the life-saving care that we deserve and need to thrive.”
The study’s findings are particularly noteworthy given the prevalence of mental health challenges within the transgender community. According to the National Institute of Mental Health, approximately 8.3% of U.S. adults experience major depression. However, a 2023 study found that around 33% of transgender individuals report symptoms of depression.
Experts attribute these disparities to systemic issues, including stigma, discrimination, and limited access to healthcare. Melina Wald, a clinical psychologist, highlighted the impact of legislative efforts targeting transgender health care, noting the sharp increase in such bills in recent years.
Dr. Michelle Forcier, medical director for FOLX Health, emphasized the significance of the study’s diverse sample, which included patients from various age, racial, and socioeconomic backgrounds. “That these patients benefited from care in these various primary care clinics in a diversity of communities suggests that effective gender affirmative hormone is no longer restricted to urban, academic, specialty clinics,” Forcier stated.
The research reinforces the safety and benefits of hormone therapy, with experts citing over 25 years of evidence supporting gender-affirming care. “We have more than 25 years of consistent, persistent, insistent evidence that gender affirmative approaches to care for transgender persons offer a variety of medical and mental health benefits,” Forcier said.
Disclaimer: This article reports on the findings of a specific study. It is important to note that correlation does not equal causation, and further research is necessary to fully understand the relationship between hormone therapy and mental health in transgender individuals. Individual experiences and outcomes may vary. This article is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional for personalized guidance regarding gender-affirming care and mental health.
